Skip to main content
. 2014 Dec 18;7(1):129–137. doi: 10.4161/19420862.2014.985489

Figure 3.

Figure 3.

In vivo efficacy of antibody ZY0NP0-E06 in Alternaria alternata challenge model of asthma. ZY0NP0-E06 or isotype control (mIgG1) were dosed at 30 mg/kg intra-peritoneal 1 day and 1 hour prior to intranasal challenge with 25 μg Alternaria alternata extract. Eosinophil numbers (A) and IL-5 levels (B) were measured in the bronchoalveolar fluid 24 hr post-challenge. Error bars correspond to ± standard error of the mean, and represent the composite of 2 independent experiments with 7–12 mice per group. Significance was determined by 1 way ANOVA with a Tukey's multiple comparison test. * 0.05 > p > 0.01, ** 0.001 > p > 0.01, *** 0.0001> p >0.001 and ****0.0001 > p.